Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

被引：8
|
作者：
Carbone, Antonino [1 ,5 ]
Gloghini, Annunziata [2 ]
Carlo-Stella, Carmelo [3 ,4 ]
机构：
[1] IRCCS, Ist Nazl Tumori, Ctr Riferimento Oncol Aviano, Dept Pathol, Aviano, Italy
[2] Fdn IRCCS, Ist Nazl Tumori, Dept Diagnost Pathol & Lab Med, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Dept Oncol & Hematol, Milan, Italy
[5] IRCCS, Ist Nazl Tumori, Ctr Riferimento Oncol Aviano, Via F Gallini 2, I-33081 Aviano, Italy
来源：
BLOOD | 2023年 / 141卷 / 18期
关键词：
REED-STERNBERG CELLS; PD-1; BLOCKADE; BRENTUXIMAB VEDOTIN; PHASE-II; T-CELLS; NIVOLUMAB; PEMBROLIZUMAB; RESISTANCE; SURVIVAL; TRANSPLANTATION;
D O I：
10.1182/blood.2022016590
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Classic Hodgkin lymphoma (cHL) is characterized by a tumor microenvironment (TME) containing inflammatory/ immune cells. Follicular lymphoma, mediastinal gray zone lymphoma, and diffuse large B-cell lymphomas may show a TME containing inflammatory/immune cells, but the TMEs are quite different. In B-cell lymphomas and cHL, programmed cell death 1 (PD-1)-PD ligand 1 pathway blockade drugs differ in their effectiveness among patients with refractory/relapsed disease. Further research should explore innovative assays that could reveal which molecules influence sensitivity or resistance to therapy in an individual patient.
引用
收藏
页码：2187 / 2193
页数：7
相关论文
共 50 条
  • [21] New key factors in the outcome of Hodgkin's lymphoma cases: Tumor microenvironment and mitotic checkpoint
    Garcia, JF
    Sanchez-Aguilera, A
    Montalban, C
    Dominguez, P
    Sanchez-Verde, L
    Morente, MM
    Garcia-Cosio, M
    Bellas, C
    Romagosa, V
    Menarguez, J
    Mestre, MJ
    Fresno, MF
    Piris, MA
    LABORATORY INVESTIGATION, 2006, 86 : 226A - 226A
  • [22] Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
    Carreau, Nicole A.
    Pail, Orrin
    Armand, Philippe
    Merryman, Reid W.
    Advani, Ranjana H.
    Spinner, Michael A.
    Herrera, Alex F.
    Chen, Robert W.
    Tomassetti, Sarah
    Ramchandren, Radhakrishnan
    Hamid, Muhammad
    Assouline, Sarit
    Santiago, Raoul
    Wagner-Johnston, Nina D.
    Paul, Suman
    Svoboda, Jakub
    Bair, Steven M.
    Barta, Stefan Klaus
    Liu, Yang
    Nathan, Sunita
    Burkart, Madelyn
    Karmali, Reem
    Torka, Pallawi
    David, Kevin A.
    Wei, Catherine
    Lansigan, Frederick
    Emery, Lukas
    Persky, Daniel
    Smith, Sonali M.
    Chavez, Julio C.
    Xia, Yuhe
    Troxel, Andrea B.
    Diefenbach, Catherine
    BLOOD, 2018, 132
  • [23] The temporal influence of the tumor microenvironment in response to checkpoint blockade
    Greenwald, Noah F.
    Nederlof, Iris
    Horlings, Hugo
    Kok, Marleen
    Curtis, Christina
    Angelo, Michael
    CANCER RESEARCH, 2024, 84 (06)
  • [24] The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
    Petitprez, Florent
    Meylan, Maxime
    de Reynies, Aurelien
    Sautes-Fridman, Catherine
    Fridman, Wolf H.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [25] Improving Outcomes With Checkpoint Blockade in Non-Hodgkin Lymphoma
    O'Brien, Susan
    Brody, Joshua
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (05) : 273 - 275
  • [26] Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
    Carreau, Nicole A.
    Armand, Philippe
    Merryman, Reid W.
    Advani, Ranjana H.
    Spinner, Michael A.
    Herrera, Alex F.
    Ramchandren, Radhakrishnan
    Hamid, Muhammad S.
    Assouline, Sarit
    Santiago, Raoul
    Wagner-Johnston, Nina
    Paul, Suman
    Svoboda, Jakub
    Bair, Steven M.
    Barta, Stefan K.
    Nathan, Sunita
    Karmali, Reem
    Torka, Pallawi
    David, Kevin
    Lansigan, Frederick
    Persky, Daniel
    Godfrey, James
    Chavez, Julio C.
    Xia, Yuhe
    Diefenbach, Catherine
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (01) : 44 - 51
  • [27] Successful Treatment of Paraneoplastic Cholestasis in Relapsed/Refractory Hodgkin Lymphoma With Bridging Therapy and Checkpoint Blockade
    Peringeth, Gopisree
    Torka, Pallawi
    Wong, Jerry
    Hernandez-Ilizaliturri, Francisco J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (06): : E316 - E319
  • [28] Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
    Lesokhin, Alexander M.
    Bal, Susan
    Badros, Ashraf Z.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (08) : 1224 - 1229
  • [29] Emerging role of checkpoint blockade therapy in lymphoma
    Galanina, Natalie
    Kline, Justin
    Bishop, Michael R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (02) : 81 - 90
  • [30] Immune-Checkpoint Blockade Therapy in Lymphoma
    Kuzume, Ayumi
    Chi, SungGi
    Yamauchi, Nobuhiko
    Minami, Yosuke
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 15
12345